Abstract: In animals including humans, the symptoms of non-anaphylactic disease states wherein the disease victim's humoral and/or cell-mediated immunological response is involved in disease pathology are alleviated upon administration of compositions comprising mixtures of histamine and one or more immunogenic substances participative in the humoral or cell-mediated pathogenic response. In preferred embodiments, the compositions are administered in essentially minute, "neutralizing" doses. Illustratively, significant relief of symptoms of multiple sclerosis is achieved through parenteral (e.g., subcutaneous or sublingual) administration of mixtures of histamine and measles virus immunogen. For a majority of patients, from about 8.8.times.10.sup.-6 to 5.5.times.10.sup.-3 mg of histamine phosphate will provide an effective quantity of histamine to a unit dose of the mixture. Likewise, a unit does of the mixture will contain from about 2.times.10.sup.-3 to about 4.times.10.sup.

Abstract: Disclosed are methods and compositions useful for alleviating the symptoms of rheumatoid arthritis. In preferred embodiments, the compositions are administered in essentially minute "neutralizing" doses. The compositions comprise mixtures of histamine, immunoglobulin G provocative of RF formation or an immunologically active fraction thereof, collagen and either attenuated measles virus or immunologically active fraction thereof. Illustratively significant relief of symptoms of arthritis disease symptoms is achieved through parenteral (e.g., subcutaneous or sublingual) administration of such compositions.

Abstract: A hybrid polypeptide composed of an identification peptide and a desired functional protein are produced by recombinant DNA techniques. A DNA expression vector is constructed that includes segments of DNA coding for the identification peptide and the desired functional protein. The identification peptide consists of a highly antigenic N-terminal portion and a C-terminal linking portion that connects the identification peptide to the N-terminal of the functional protein. The linking portion of the identification peptide is cleavable at a specific amino acid residue adjacent the functional protein by use of a sequence specific proteolytic enzyme or chemical proteolytic agent. The hybrid polypeptide expressed by the host cells transformed by the cloning vector is removed therefrom and purified by affinity chromatography techniques by use of an immobilized ligand specific to the antigenic portion of the identification peptide.

Abstract: A novel feline fibroblastic cell line infected with Snyder-Theilen feline leukemia virus is provided. The cell line produces large amounts of FeLV when cultured in a medium free from serum supplement. The latter aspect is a substantial advantage since it reduces the expense of culturing and eliminates the need to separate serum from culture medium prior to preparing a vaccine.Feline fibroblastic cell line FF64/280 was deposited at the American Type Culture Collection on Apr. 17, 1984, and granted accession no. VR 2085.

Abstract: Disclosed are compositions for the treatment of cancer, such as lymphomas and solid tumors, methods of producing these compositions, and methods and regimens in using these compositions in the treatment of hosts having cancer.

Abstract: Recombinant DNA vector including (1) a promoter for a eukaryotic metalliothionein gene ligated to a gene sequence encoding hepatitis B surface antigen, and (2) at least the 69% transforming region of the bovine papilloma genome, expression of the hepatitis B surface antigen encoding gene sequence being under the control of the metallothionein promoter.

Abstract: The invention relates to a process for the preparation of .alpha.- and .gamma.-interferon by isolating the buffy coat fraction of blood, removing the erythrocytes, suspending the leukocytes in a suitable nutrient medium and treating with an .alpha.-interferon inducer and with a .gamma.-interferon inducer, which comprises producing .alpha.-interferon and .gamma.-interferon one after the other in the same leukocyte culture by pre-treating the suspension obtained after the separation of the leukocyte/buffy coat/fraction of blood, removal of the erythrocytes and suspending the leukocytes in a suitable nutrient medium with - or .beta.-interferon, contacting with an .alpha.-interferon inducer, separating the liquid containing the .alpha.-interferon from the cells, if desired recovering the -interferon, washing and suspending the cells in a suitable nutrient medium, treating with a mitogenic agent, separating the liquid comprising .alpha.-interferon from the cells and if desired recovering .alpha.

Abstract: Described are rapid and highly efficient procedures for the total synthesis of linear, double stranded DNA sequences in excess of about 200 base pairs in length, which sequences may comprise entire structural genes. Novel sequences are prepared from two or more DNA subunits provided with terminal regions comprising restriction endonuclease cleavage sites facilitating insertion of subunits into a selected vector for purposes of amplification during the course of the total assembly process. The total, finally-assembled assembled sequences include at least one, and preferably two or more, unique restriction endonuclease cleavage site(s) at intermediate positions along the sequence, allowing for easy excision and replacement of subunits and the correspondingly facile preparation of multiple structural analogs of polypeptides coded for by the sequences.

Abstract: DNA sequences, recombinant DNA molecules and processes for producing bovine growth hormone-like polypeptides in high yield and the novel polypeptides produced thereby. These polypeptides are useful in improving the rate of growth of and meat production and quality in cattle.

Abstract: A dry .gamma.-globulin preparation capable of intravenous injection which is obtainable by polyethylene glycol fractionation of plasma is improved in its water-solubility and stability against increase of anticomplement activity and decrease of antibody titer by purifying the .gamma.-globulin fraction with respect to protein to render the residual polyethylene glycol substantially not detectable in its 5% W/V solution, adding 0.2 to 2 parts by weight of glucose based on 1 part of .gamma.-globulin, and lyophilizing its solution.

Abstract: A method of preparing an autogenous vaccine for use in improving the immunocompetence of animals affected with neoplastic disease characterized by the production of choronic gonadotropin by the microorganism Progenitor cryptocides, ATCC 31, 874.

Abstract: The production of stable hybrid cell lines that secrete human monoclonal antibodies against bacterial toxins by fusing post-immunization human peripheral blood lymphocytes with nonsecretor mouse myeloma cells is described. Using the method, protective monoclonal antibodies against tetanus toxin and diphtheria toxin were produced that bind tetanus toxin and diphtheria toxin in vitro, respectively, and prevent tetanus and diphtheria in vivo in animals, respectively.

Abstract: Induction of immune response is achieved by implantation of an antigen-impregnated substrate in the peritoneal cavity of a mammal. Immunogenic implants adapted to be implanted in mammals and the preparation thereof are also disclosed.

Abstract: Mammals immunized with an innoculum containing TLCK-treated and killed Leishmania cells show an increased resistance to Leishmaniasis.

Abstract: There is described a method of inactivating reproducible pathogens in preparations containing plasmatic enzymes and proenzymes, activated or non-activated coagulation factors, such as Factors II, V, VII, VIII, IX, X, XIII, "FEIBA", prothrombin complex preparations, plasmatic inhibitors, immunoglobulins or other blood products, such as fibronectin and fibrinogen. In order to break and overcome the protective effect of proteins on pathogens by simultaneously preserving the biological activity and the molecular integrity of the proteins, the preparation is adjusted to a salt concentration of more than 0.5 molar by the addition of ammonium sulfate and is thermally treated, whereupon the ammonium sulfate is removed from the preparation.

Abstract: Monomeric human .gamma.-interferon is efficiently produced by subjecting crude human .gamma.-interferon to gel filtration in the presence of a reducing sulfur compound and a protein-denaturing agent.

Abstract: The invention relates to a process for the isolation and purification of .alpha.-interferons generated by plasmids from bacterial cultures which have been modified by genetic engineering, and of .alpha.-interferons from culture supernatants of induced mammalian cells, which comprises partition of appropriate crude substances containing interferon between an aqueous urea solution, which contains a surfactant, and a mixture of n-butanol and glacial acetic acid which contains water, and isolation of the purified .alpha.-interferons from the upper phase.

Abstract: An intact human immune interferon protein and a method for the extraction and purification of intact recombinant human immune interferon is disclosed. This method permits the purification to homogenity of intact recombinant human immune interferon.

Abstract: The present invention relates to a vaccine composition for the prevention of infectious diseases comprising an immunogenically-effective amount of a genetically attenuated and stable avirulent bacterial strain derived from a virulent bacterial strain by introducing into said virulent strain by genetic transfer and recombination at least two mutations of the same phenotype which renders said virulent strain avirulent, while permitting said avirulent strain to retain immunogenicity, together with an inert pharmacologically acceptable carrier. It also relates to a method for preparing the vaccine.

Abstract: Hybrid cell line for producing of monoclonal antibody to an antigen found on all normal human T cells. The hybrid is formed by fusing splenocytes from immunized Balb/cJ mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.